Cassava Sciences (SAVA)

• Market cap: $147M
• 1 day: 3.73%
• 5 days: -22.14%
• 1 month: -87.21%
• 3 months: -89.61%
• 6 months: -85.20%
• Year to date: -86.35%
• 1 year: -79.88%
• 5 years: 137.21%
• 10 years: -66.56%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Employees: 29

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

146% more capital invested

Capital invested by funds: $167M [Q2] → $411M (+$244M) [Q3]

56% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 32

50% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 24

8% more funds holding

Funds holding: 146 [Q2] → 158 (+12) [Q3]

1.04% more ownership

Funds ownership: 28.16% [Q2] → 29.2% (+1.04%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

56% less call options, than puts

Call options by funds: $81M | Put options by funds: $183M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $116 3,691% upside
• Avg. target: $116 3,691% upside
• High target: $116 3,691% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

HC Wainwright & Co. Vernon Bernardino 35% 1-year accuracy 15 / 43 met price target	3,691% upside $116	Neutral Downgraded	26 Nov 2024
HC Wainwright & Co. Vernon Bernardino 35% 1-year accuracy 15 / 43 met price target	3,691% upside $116	Buy Reiterated	8 Nov 2024
HC Wainwright & Co. Vernon Bernardino 35% 1-year accuracy 15 / 43 met price target	3,691% upside $116	Buy Upgraded	8 Oct 2024